Phase I study of TrasGEX, a glyco-optimised anti-HER2 monoclonal antibody, in patients with HER2-positive solid tumours

PURPOSE: TrasGEX is a second-generation monoclonal antibody of trastuzumab, glyco-optimised to enhance antibody-dependent cellular cytotoxicity while fully retaining trastuzumab’s antigen-binding properties to human epidermal growth factor receptor 2 (HER2). A phase I dose-escalation study was condu...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:ESMO Open
Main Authors: Fiedler, Walter, Stoeger, Herbert, Perotti, Antonella, Gastl, Guenther, Weidmann, Jens, Dietrich, Bruno, Baumeister, Hans, Danielczyk, Antje, Goletz, Steffen, Salzberg, Marc, De Dosso, Sara
Formato: Artigo
Idioma:Inglês
Publicado em: BMJ Publishing Group 2018
Assuntos:
Original Research
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6045773/
https://ncbi.nlm.nih.gov/pubmed/30018811
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/esmoopen-2018-000381
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados